Product logins

Find logins to all Clarivate products below.

home   •  Research Reports  •  Disease Landscape and Forecast Insights
$24,750.00   |  '

Coronavirus COVID-19 – Executive Insights – Nonhospitalized COVID-19 Patients Executive Insights

Login to access report north_east
Buy report north_east

The treatment landscape for COVID-19 continues to evolve rapidly. Despite the availability of vaccines in the markets under study, ongoing research focuses on decreasing viral loads and improving outcomes for nonhospitalized SARS-CoV-2 patients. While multiple therapies have been approved for the treatment of COVID-19 in the markets under study, most notably Pfizer’s Paxlovid (ritonavir/nirmatrelvir), Gilead’s Veklury (remdesivir), and Merck’s molnupiravir, treatment guidelines in these regions and/or available clinical evidence do not always support the use of all available drugs. Nevertheless, given the high burden of this disease to healthcare systems worldwide, such treatments may be used to address the high unmet need in nonhospitalized settings. Numerous drugs with diverse mechanisms of action are in clinical development for nonhospitalized COVID-19 patients, many of which are expected to launch in the next couple of years. The greater availability of treatment options will continue to transform the treatment landscape and help address the existing unmet need.

QUESTIONS ANSWERED

  • What evidence exists for the use of current therapies as treatments for nonhospitalized COVID-19 patients?
  • What is the treatment algorithm for nonhospitalized COVID-19 patients?
  • What is the state of the pipeline for drugs for nonhospitalized COVID-19 patients?
  • What are the key areas of unmet need and opportunity for the treatment of nonhospitalized COVID-19 patients? What is the expected impact of therapies in development on the disease treatment and the market?

PRODUCT DESCRIPTION

Executive Insights provides indication-specific market intelligence with world-class epidemiology, keen insight into current treatment paradigms, biotherapeutic pipelines, key clinical unmet needs, and competitive landscapes, supported by primary and secondary research. This solution provides succinct insights to any biopharma function or business professional looking to quickly grasp a new indication of interest.

KEY COMPANIES COVERED

Eli Lilly, Gilead, GlaxoSmithKline, Merck, Pfizer, Regeneron, Sanofi

KEY DRUGS COVERED

Paxlovid (nirmatrelvir/ritonavir), Molnupiravir, Xevudy (sotrovimab), Veklury (remdesivir), REGN-COV2 (casirivimab/imdevimab), LY-CoV555 and LY-CoV016, and other Phase III assets.

GEOGRAPHY

United States, France, Germany, United Kingdom, Japan

PRIMARY RESEARCH

12 KOL interviews in March 2022

Table of contents

Buy report north_east
Login to access report north_east

Related Market Assessment Reports

Report
Rheumatoid Arthritis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Rheumatoid Arthritis (US)
The treatment of rheumatoid arthritis (RA) typically begins with cost-effective conventional DMARDs (cDMARDs) such as methotrexate or hydroxychloroquine. For patients who fail cDMARD treatment or…
north_east
Report
Heart Failure – Current Treatment – Treatment Algorithms: Claims Data Analysis – Heart Failure with Reduced Ejection Fraction (US)
Drug treatment of heart failure with reduced ejection fraction (HFrEF) is well established, backed by a wealth of supporting evidence from clinical trials. RAAS inhibitors and beta blockers are the…
north_east
Report
Immune Thrombocytopenic Purpura – Current treatment – Treatment Algorithms: Claims Data Analysis – Immune Thrombocytopenic Purpura (US)
Immune thrombocytopenic purpura (ITP) is an autoimmune disorder characterized by a low platelet count, resulting in an increased risk of bleeding. Current therapies for ITP can be largely divided…
north_east
Report
Migraine – Current Treatment – Treatment Algorithms: Claims Data Analysis – Migraine Prophylaxis (US)
Migraine is a neurological condition characterized by moderate to severe headaches; it can have a major impact on patients’ quality of life. Our quantitative analysis of treatment patterns…
north_east
Report
Primary Biliary Cholangitis – Landscape & Forecast – Niche & Rare Disease Landscape & Forecast (US/EU5)
Primary biliary cholangitis (PBC) is a rare autoimmune liver disease, characterized by inflammation and progressive damage leading to destruction of interlobular bile ducts, followed by cholestasis…
north_east

Follow us

Contact us

Sales enquiries north_east
Customer service north_east
Support north_east